Home > E. Pathology by systems > Reproductive system > Male genital system > Prostate > prostate carcinoma with neuroendocrine differentiation
prostate carcinoma with neuroendocrine differentiation
Tuesday 23 December 2014
prostate cancer with neuroendocrine differentiation
On July 31, 2013, the Prostate Cancer Foundation assembled a working committee on the molecular biology and pathologic classification of neuroendocrine (NE) differentiation in prostate cancer. New clinical and molecular data emerging from prostate cancers treated by contemporary androgen deprivation therapies, as well as primary lesions, have highlighted the need for refinement of diagnostic terminology to encompass the full spectrum of NE differentiation.
The classification system consists of:
Usual prostate adenocarcinoma with NE differentiation;
Adenocarcinoma with Paneth cell NE differentiation;
Carcinoid tumor;
Small cell carcinoma;
Large cell NE carcinoma;
Mixed NE carcinoma - acinar adenocarcinoma.
It also includes "prostate carcinoma with overlapping features of small cell carcinoma and acinar adenocarcinoma" and "castrate-resistant prostate cancer with small cell cancer-like clinical presentation".
Open references
Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, Robinson BD, Troncoso P, Rubin MA. Am J Surg Pathol. 2014 Jun;38(6):756-67. doi : 10.1097/PAS.0000000000000208 PMID: 24705311 [Free]
